Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006486 · ClinicalTrials.gov registry record · Phase 2
Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 335
- Enrollment target
NCT00006486: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00006486 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 335 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006486, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 335 participants
- Enrollment target
Study Summary
Randomized phase II trial to study the effectiveness of carboxyamidotriazole in treating patients who have metastatic kidney cancer. Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor
Interventions
- OTHER placebo
- DRUG carboxyamidotriazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2000-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006486
The ClinicalTrials.gov registry entry for NCT00006486 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 335 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00006486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006486 about?
NCT00006486 is a clinical study titled "Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer". Randomized phase II trial to study the effectiveness of carboxyamidotriazole in treating patients who have metastatic kidney cancer. Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor
What is the current status of trial NCT00006486?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 335 participants. The study started on 2000-10.
What interventions are being tested in trial NCT00006486?
The interventions under investigation include: placebo (OTHER), carboxyamidotriazole (DRUG).
Who is sponsoring clinical trial NCT00006486?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.